NR1H4 and obesity disorder: Recent studies in which mice on a HFD were treated with the gut microbiota-modifying agent tempol or antibiotics, suggested that inhibition of intestinal FXR signalling could be of benefit in amelioration of obesity, insulin resistance and non-alcoholic fatty liver disease10, 11.